European Study of Cardiovascular Risk (EURIKA)
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
The patient's participation consists of a single study visit during a routine visit of the patient to the clinic/office.
Study variables will be measured:
- By an interview between physician and patient during the visit and/or available medical records' information: social and demographic patient characteristics, relevant family medical history, current medication.
- By questions asked to the physician: physician perception of patients' CV risk factor, guidelines adherence and cost-containment.
- By measurement performed to the patient during the visit: weight, height, BMI, waist and hip circumference will be measured.
- CV risk factors (blood parameters) will be measured by collecting available data documented within the last year in the medical records and by the collection and analyses of a blood sample during the visit.
Cardiovascular Risk Factors
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice|
- LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
- Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history. [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
- BMI, Score based 10 year CHD mortality > 5%, High Risk patients (no. and %) [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
- Use of concomitant medication: anticoagulant, anti hypertensive, antidiabetic, lipid-lowering drugs [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
- Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate. [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Whole blood Serum
|Study Start Date:||May 2009|
|Study Completion Date:||October 2009|
Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00882336
Show 778 Study Locations
|Study Director:||Elvira Massó||AstraZeneca Spain|